GU Cancers 2023 | The role of ICIs in the adjuvant setting for RCC

Matthew R. Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the Phase III S-TRAC trial (NCT00375674) which investigated sunitinib vs. placebo in the adjuvant setting for patients with renal cell carcinoma (RCC). Dr Zibelman also discusses the role of immune checkpoint inhibitors (ICIs) in the adjuvant setting for patients with RCC. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.